DAX23.591 -0,9%Est505.720 -1,1%MSCI World4.343 -0,1%Top 10 Crypto8,8900 -7,4%Nas22.388 -1,6%Bitcoin58.750 +0,2%Euro1,1619 ±0,0%Öl92,69 +9,9%Gold5.171 +1,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg weitet sich aus: DAX geht schwach ins Wochenende -- US-Börsen tiefer -- Lufthansa auf Wachstumskurs -- US-Chipaktien, TeamViewer, Oracle, Rüstungsaktien, Marvell, DroneShield im Fokus
Top News
Das waren die 10 größten NFT-Flops der Promis Das waren die 10 größten NFT-Flops der Promis
Gabler-Aktie steuert auf Börsengang zu: Sollten Anleger beim neuen Rüstungswert zugreifen? Gabler-Aktie steuert auf Börsengang zu: Sollten Anleger beim neuen Rüstungswert zugreifen?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

MaaT Pharma Aktie

Kaufen
Verkaufen
6,82 EUR -0,16 EUR -2,29 %
BMN
6,98 EUR +0,10 EUR +1,45 %
PAR
finanzen.net zero
MaaT Pharma jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.129,51 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3C7A5

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0012634822

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolMATPF

MaaT Pharma Aktien News

DatumMeistgelesen
BusinesswireMaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
BusinesswireCORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
BusinesswireMaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
Wer­bungMaaT Pharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireMaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
BusinesswireMaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
BusinesswireMaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
BusinesswireMaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
BusinesswireMaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
BusinesswireMaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
BusinesswireMaaT Pharma To Present and Participate in Investor and Medical Conferences in September
BusinesswireMaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
BusinesswireMaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
BusinesswireMaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
BusinesswireMaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros
BusinesswireMaaT Pharma Launches a Global Offering of approximately 18 Million Euros
BusinesswireMaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
BusinesswireMaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
BusinesswireMaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
BusinesswireMaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference
BusinesswireMaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
BusinesswireMaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
BusinesswireMaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
BusinesswireMaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
BusinesswireMaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
BusinesswireMaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
BusinesswireMaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
BusinesswireMaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
BusinesswireMaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
BusinesswireMaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
BusinesswireMaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
BusinesswireMaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation
BusinesswireMaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
BusinesswireMaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
BusinesswireMaaT Pharma Joins Microbiome Therapeutics Innovation Group
BusinesswireMaaT Pharma Announces New Appointments to the Board and Executive Team
BusinesswireMaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
BusinesswireMaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
BusinesswireMaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting
BusinesswireMaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
BusinesswireMaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe

MaaT Pharma News

MaaT Pharma News: auf dieser Seite finden Sie alle MaaT Pharma News und Nachrichten zur MaaT Pharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MaaT Pharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MaaT Pharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.